Lumos Pharma Valuation
| LUMO Stock | USD 4.30 0.01 0.23% |
At this time, the firm appears to be undervalued. Lumos Pharma secures a last-minute Real Value of $8.07 per share. The latest price of the firm is $4.3. Our model forecasts the value of Lumos Pharma from analyzing the firm fundamentals such as Operating Margin of (10.52) %, shares outstanding of 8.65 M, and Return On Equity of -1.73 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Lumos Pharma's valuation include:
Price Book 7.5856 | Enterprise Value 23.9 M | Enterprise Value Ebitda 0.3853 | Price Sales 16.905 | Enterprise Value Revenue 10.8519 |
Undervalued
Today
Please note that Lumos Pharma's price fluctuation is somewhat reliable at this time. Calculation of the real value of Lumos Pharma is based on 3 months time horizon. Increasing Lumos Pharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Lumos Pharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Lumos Stock. However, Lumos Pharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 4.3 | Real 8.07 | Target 20.2 | Hype 4.29 | Naive 4.2 |
The intrinsic value of Lumos Pharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Lumos Pharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Lumos Pharma helps investors to forecast how Lumos stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Lumos Pharma more accurately as focusing exclusively on Lumos Pharma's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Lumos Pharma's intrinsic value based on its ongoing forecasts of Lumos Pharma's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Lumos Pharma's closest peers.
Lumos Pharma Cash |
|
Lumos Valuation Trend
Knowing Lumos Pharma's actual value is paramount for traders when making sound investment determinations. Using both Lumos Pharma's enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Lumos Pharma Total Value Analysis
Lumos Pharma is now expected to have valuation of 23.93 M with market capitalization of 37.28 M, debt of 585 K, and cash on hands of 79.51 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Lumos Pharma fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
23.93 M | 37.28 M | 585 K | 79.51 M |
Lumos Pharma Investor Information
About 33.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 4.28. Lumos Pharma last dividend was issued on the 19th of March 2020. The entity had 1:9 split on the 19th of March 2020. Based on the key measurements obtained from Lumos Pharma's financial statements, Lumos Pharma is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December.Lumos Pharma Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Lumos Pharma has an asset utilization ratio of 5.05 percent. This suggests that the Company is making $0.0505 for each dollar of assets. An increasing asset utilization means that Lumos Pharma is more efficient with each dollar of assets it utilizes for everyday operations.Lumos Pharma Ownership Allocation
The market capitalization of Lumos Pharma is $37.28 Million. Lumos Pharma holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.Lumos Pharma Profitability Analysis
The company reported the previous year's revenue of 2.05 M. Net Loss for the year was (34.03 M) with profit before overhead, payroll, taxes, and interest of 1.52 M.About Lumos Pharma Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Lumos Pharma. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Lumos Pharma based exclusively on its fundamental and basic technical indicators. By analyzing Lumos Pharma's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Lumos Pharma's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Lumos Pharma. We calculate exposure to Lumos Pharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Lumos Pharma's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 2 M | 1.9 M | |
| Pretax Profit Margin | (16.61) | (17.44) | |
| Operating Profit Margin | (17.85) | (18.74) | |
| Net Loss | (16.59) | (17.42) | |
| Gross Profit Margin | 0.87 | 1.68 |
Lumos Pharma Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 8.1 M |
Lumos Pharma Current Valuation Indicators
Lumos Pharma's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Lumos Pharma's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Lumos Pharma, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Lumos Pharma's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Lumos Pharma's worth.When determining whether Lumos Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lumos Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lumos Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lumos Pharma Stock: Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lumos Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. To learn how to invest in Lumos Stock, please use our How to Invest in Lumos Pharma guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lumos Pharma. If investors know Lumos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lumos Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.28) | Revenue Per Share 0.27 | Quarterly Revenue Growth 102.714 | Return On Assets (0.70) | Return On Equity (1.73) |
The market value of Lumos Pharma is measured differently than its book value, which is the value of Lumos that is recorded on the company's balance sheet. Investors also form their own opinion of Lumos Pharma's value that differs from its market value or its book value, called intrinsic value, which is Lumos Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lumos Pharma's market value can be influenced by many factors that don't directly affect Lumos Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lumos Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lumos Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lumos Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.